JP2012512257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512257A5 JP2012512257A5 JP2011542431A JP2011542431A JP2012512257A5 JP 2012512257 A5 JP2012512257 A5 JP 2012512257A5 JP 2011542431 A JP2011542431 A JP 2011542431A JP 2011542431 A JP2011542431 A JP 2011542431A JP 2012512257 A5 JP2012512257 A5 JP 2012512257A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- item
- polypeptide antigen
- polypeptide
- chlamydia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13826108P | 2008-12-17 | 2008-12-17 | |
| US61/138,261 | 2008-12-17 | ||
| PCT/US2009/068457 WO2010078027A1 (en) | 2008-12-17 | 2009-12-17 | Chlamydia antigens and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012512257A JP2012512257A (ja) | 2012-05-31 |
| JP2012512257A5 true JP2012512257A5 (enExample) | 2013-02-07 |
Family
ID=42310157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542431A Pending JP2012512257A (ja) | 2008-12-17 | 2009-12-17 | クラミジア抗原およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110293664A1 (enExample) |
| EP (1) | EP2379106A4 (enExample) |
| JP (1) | JP2012512257A (enExample) |
| AU (1) | AU2009333159A1 (enExample) |
| CA (1) | CA2781805A1 (enExample) |
| WO (1) | WO2010078027A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US9259463B2 (en) * | 2006-01-16 | 2016-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Chlamydia vaccine |
| CN106924728B (zh) | 2009-05-22 | 2021-02-05 | 健诺西生物科学公司 | 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法 |
| WO2011112906A2 (en) | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Novel immunogens and methods for discovery and screening thereof |
| CA2849391A1 (en) * | 2010-10-20 | 2012-04-26 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
| WO2012074881A2 (en) | 2010-11-24 | 2012-06-07 | Genocea Biosciences, Inc. | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| JP6199878B2 (ja) * | 2011-11-23 | 2017-09-20 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法 |
| WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| WO2018064232A1 (en) | 2016-09-28 | 2018-04-05 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
| JP2021535921A (ja) | 2018-09-12 | 2021-12-23 | アフィニバックス、インコーポレイテッド | 多価肺炎球菌ワクチン |
| WO2023039223A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9814912A (pt) * | 1997-11-28 | 2000-10-03 | Genset Sa | Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção |
| EP1133572A4 (en) * | 1998-11-12 | 2005-06-15 | Univ California | GENOMIC SEQUENCE OF CHLAMYDIA PNEUMONIAE |
| US6822071B1 (en) * | 1998-11-12 | 2004-11-23 | The Regents Of The University Of California | Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease |
| ES2312649T3 (es) * | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
| GB0203403D0 (en) * | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| US20090028891A1 (en) * | 2004-11-11 | 2009-01-29 | Queensland University Of Technology | Chlamydia Antigens and Uses Thereof |
-
2009
- 2009-12-17 WO PCT/US2009/068457 patent/WO2010078027A1/en not_active Ceased
- 2009-12-17 US US13/140,773 patent/US20110293664A1/en not_active Abandoned
- 2009-12-17 EP EP09836943A patent/EP2379106A4/en not_active Withdrawn
- 2009-12-17 CA CA2781805A patent/CA2781805A1/en not_active Abandoned
- 2009-12-17 JP JP2011542431A patent/JP2012512257A/ja active Pending
- 2009-12-17 AU AU2009333159A patent/AU2009333159A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512257A5 (enExample) | ||
| Cunningham et al. | Vaccine development: From concept to early clinical testing | |
| Dziadek et al. | Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice | |
| JP2023162283A5 (enExample) | ||
| Rafati et al. | Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis | |
| RU2490024C2 (ru) | Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли | |
| Reed et al. | Correlates of GLA family adjuvants’ activities | |
| JP2013545448A5 (enExample) | ||
| JP2012152228A (ja) | 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸 | |
| TW200722101A (en) | Novel composition | |
| JP2016106117A5 (enExample) | ||
| Kabiri et al. | Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles | |
| Ni et al. | Protection against scrub typhus by a plasmid vaccine encoding the 56-KD outer membrane protein antigen gene | |
| El-Malky et al. | Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations | |
| Irache et al. | Poly (anhydride) nanoparticles as adjuvants for mucosal vaccination | |
| Maraghi et al. | Evaluation of immunogenicity and protective effect of DNA vaccine encoding surface antigen1 (SAG1) of Toxoplasma gondii and TLR-5 ligand as a genetic adjuvant against acute toxoplasmosis in BALB/c mice | |
| WO2005042564A1 (en) | Flagellin fusion proteins as adjuvants or vaccines and methods of use | |
| Da Fonseca et al. | Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis | |
| Batzloff et al. | Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease | |
| ElSherif et al. | Benefits of Combining Molecular Biology and Controlled Human Infection Model Methodologies in Advancing Vaccine Development | |
| US20040115210A1 (en) | Imunogenic complex comprising ribosomes | |
| Kano et al. | Induced immune response of DNA vaccine encoding an association MSP1a, MSP1b, and MSP5 antigens of Anaplasma marginale | |
| Carneiro et al. | Vaccine engineering & structural vaccinology | |
| Olszewska et al. | Nasal delivery of epitope based vaccines | |
| Lowell et al. | Proteosome™ technology for vaccines and adjuvants |